< Back to search
Filter
1
Featured

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for
Non Small Cell Lung Cancer
Location: Levis, Greenfield Park, Montreal, Brampton,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT04928846

Phase3, Recruiting
Featured

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

for
Non-Small Cell Lung Cancer
Location: New Haven CT, Mineola NY, The Bronx NY, New York NY,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT05789082

Phase1, Phase2, Recruiting
Featured

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for
Non-Small Cell Lung Cancer
Location: New Haven CT, Westbury NY, The Bronx NY, Teaneck NJ,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06568939

Phase2, Recruiting
Featured

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

for
Non-small Cell Lung Cancer
Location: Boston MA, New Haven CT, Lebanon NH, New York NY,
Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT04302025

Phase2, Recruiting
Featured

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

for
Small Cell Lung Cancer
Location: Boston MA, Bethlehem PA, Fairfax VA, Winchester VA,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07365241

Phase3, Recruiting

Interested in new lung cancer trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Featured

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for
Non-Small Cell Lung Cancer
Location: Greensboro NC, Winter Haven FL, Athens GA,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06236438

Phase2, Phase3, Recruiting
Featured

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

for
Small Cell Lung Cancer
Location: Boston MA, New Haven CT, Fairfax VA, Ocala FL, Tampa FL,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07155174

Phase2, Recruiting
Featured

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

for
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Location: Rimouski, Boston MA, Worcester MA, Hartford CT, Quebec,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06793215

Phase3, Recruiting
Featured

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

for
Non-cystic Fibrosis Bronchiectasis,
Location: Chapel Hill NC, Pittsburgh PA, Birmingham AL,
Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT06603246

Phase1, Recruiting
Featured

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

for
Idiopathic Pulmonary Fibrosis
Location: Trois-Rivieres, Philadelphia PA, Richmond VA,
Sponsor: AbbVie

Sex: All

Age: 40+

Code: NCT07230288

Phase2, Recruiting
Featured

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

for
Non Small Cell Lung Carcinoma
Location: Boston MA, Shirley NY, East Brunswick NJ, Easton PA,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06772623

Phase1, Phase2, Recruiting
Featured

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

for
Metastatic Pancreatic Ductal Adenocarcinoma, PDAC
Location: Philadelphia PA, Fairfax VA, Cleveland OH,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07490301

Phase2, Phase3, Recruiting
Active & Responsive

Lung Cancer Biomarkers and Screening

for
Lung Cancer
Location: New York NY
Sponsor: NYU Langone Health

Sex: All

Age: 50+

Code: NCT00301119

Recruiting
Active & Responsive

Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer

for
Small-cell Lung Cancer
Location: Atlanta GA
Sponsor: Emory University

Sex: All

Age: 18+

Code: NCT04342429

Recruiting
Active & Responsive

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

for
Non-Small Cell Lung Cancer
Location: Neptune City NJ, Montreal, Syracuse NY, Ottawa, Toronto,
Sponsor: University of Texas Southwestern Medical Center

Sex: All

Age: 18+

Code: NCT02468024

Phase3, Recruiting
Active & Responsive

Temple Health Chest Initiative (THCI 2.0)

for
Chronic Obstructive Pulmonary Disease (COPD)
Location: Philadelphia PA
Sponsor: Temple University

Sex: All

Age: 50 - 70+

Code: NCT06933758

Recruiting
Active & Responsive

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

for
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma,
Location: Boston MA, New York NY, Fairfax VA, Durham NC,
Sponsor: Alterome Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06835569

Phase1, Recruiting
Active & Responsive

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),
Location: Fort Worth TX, Los Angeles CA
Sponsor: iLeukon Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07452224

Phase2, Recruiting
Active & Responsive

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

for
Cancer, Breast Cancer, Lung Cancer, Colon Cancer,
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT03702309

Recruiting
Active & Responsive

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

for
Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung,
Location: New York NY, Jacksonville FL, Tampa FL, Columbus OH,
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT06682793

Phase1, Phase2, Recruiting